The Influence of GBA and LRRK2 on Mood Disorders in Parkinson's Disease
Movement Disorders Clinical Practice · 2023-04 · 10 (4) · 606-616
DOI: 10.1002/mdc3.13722 ↗Kurz gefasst
Fachartikel in der Zeitschrift Movement Disorders Clinical Practice, online erschienen am 21.03.2023. Verfasst von Jake DeBroff und 11 weiteren Autor:innen. Beteiligte Einrichtung: Sackler School of Medicine Tel-Aviv University. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Biogen.
Abstract (Originalsprache)
Background
Mood disorders have emerged as major non‐motor comorbidities in Parkinson's disease (PD) even at the prodromal stage of the disease. Mutations in the LRRK2 and GBA genes are common among Ashkenazi Jews, with more severe phenotype reported for GBA ‐PD.
Objective
To explore the association between genetic status and mood related disorders before and after diagnosis of PD and the association between mood‐related medications, phenotype, and genetic status.
Methods
Participants were genotyped for mutations in the LRRK2 and GBA genes. State of depression, anxiety and non‐motor features were evaluated using validated questionnaires. History of mood disorders prior to diagnosis of PD and use of mood‐related medications were assessed.
Results
The study included 105 idiopathic PD (iPD), 55 LRRK2 ‐PD and 94 GBA ‐PD. Scores on mood related questionnaires and frequency of depression and anxiety before diagnosis were similar between the groups ( p >0.05). However, more GBA ‐PD patients used mood related medications before PD diagnosis than LRRK2 ‐PD and iPD (16.5% vs 7.1% and 8.2%, p =0.044). LRRK2 ‐PD and GBA ‐PD receiving mood‐related medications at time of assessment had worse motor and non‐motor phenotype compared to those that did not ( p
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Sackler School of Medicine Tel-Aviv University.
- Movement Disorders Unit Neurological Institute, Tel-Aviv Medical Center.
- Laboratory of Early Markers of Neurodegeneration Neurological Institute, Tel-Aviv Medical Center.
- Sagol School of Neuroscience Tel-Aviv University.
- Neurology department Meir Hospital Kfar-Saba Israel.
- Biogen Inc. Cambridge MA USA.
ORCID-Profile: Anat Mirelman, Avner Thaler
Förderung
- Biogen
Zitieren
APA
DeBroff, J., Omer, N., Cohen, B., Giladi, N., Kestenbaum, M., Shirvan, J. C., Cedarbaum, J. M., Gana-Weisz, M., Goldstein, O., Orr-Urtreger, A., Mirelman, A., & Thaler, A. (2023). The Influence of GBA and LRRK2 on Mood Disorders in Parkinson's Disease. Movement Disorders Clinical Practice, 10(4), 606-616. https://doi.org/10.1002/mdc3.13722
Vancouver
DeBroff J, Omer N, Cohen B, Giladi N, Kestenbaum M, Shirvan JC, et al. The Influence of GBA and LRRK2 on Mood Disorders in Parkinson's Disease. Movement Disorders Clinical Practice. 2023;10(4):606-616. doi:10.1002/mdc3.13722
BibTeX
@article{DeBroff2023,
author = {DeBroff, Jake and Omer, Nurit and Cohen, Batsheva and Giladi, Nir and Kestenbaum, Meir and Shirvan, Julia C and Cedarbaum, Jesse M and Gana-Weisz, Mali and Goldstein, Orly and Orr-Urtreger, Avi and Mirelman, Anat and Thaler, Avner},
title = {The Influence of GBA and LRRK2 on Mood Disorders in Parkinson's Disease},
journal = {Movement Disorders Clinical Practice},
year = {2023},
volume = {10},
number = {4},
pages = {606--616},
doi = {10.1002/mdc3.13722}
}
EUVIMED